Skip to main content

CSCIF 6-K/A

COSCIENS Biopharma Inc. (CSCIF)

6-K/A 2024-05-30 For: 2023-05-29
View Original
Added on August 22, 2026

UNITEDSTATES

SECURITIESAND EXCHANGE COMMISSION

Washington,D.C. 20549

FORM6-K/A

REPORTOF FOREIGN PRIVATE ISSUER

PURSUANTTO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2024

Commission File Number: 001-38064

AeternaZentaris Inc.

(Translation of registrant’s name into English)

c/oNorton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

ExplanatoryNote

This Amendment No. 1 to this Report on Form 6-K/A (this “Amendment”), originally furnished to the U.S. Securities and Exchange Commission (the “Commission”) on May 15, 2024 (the “Original Form 6-K”), is being furnished to the Commission by Aeterna Zentaris Inc. (the “Company”) solely to include the conformed signature on the consent of Raymond Chabot Grant Thornton LLP (the “Consent”) attached as Exhibit 23.1 to the Original Form 6-K that was erroneously omitted from the Original Form 6-K. The Consent with the conformed signature is attached as Exhibit 23.1 to this Amendment and replaces the Consent attached as Exhibit 23.1 to the Original Form 6-K in its entirety, and is incorporated by reference herein and in the Original Form 6-K by this reference.

Other than as expressly set forth above, this Amendment does not, and does not purport to, amend, update or restate the information contained in the Original Form 6-K, or reflect any events that have occurred after the Original Form 6-K was originally furnished to the Commission.

DOCUMENTSINDEX

Exhibit Description
Exhibit<br> 23.1 Consent of Raymond Chabot Grant Thornton LLP

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.
Date:<br> May 29, 2024 By: /s/ Giuliano La Fratta
Giuliano<br> La Fratta
Chief<br> Financial Officer

Exhibit 23.1

**** RaymondChabot Grant Thornton LLP
**** Suite 2000 <br><br>National<br>Bank Tower
**** 600<br>De La Gauchetière Street West <br><br>Montréal, Quebec
**** H3B<br>4L8
Consent of Independent Registered
Public Accounting Firm T514-878-2691

We have issued our report dated April 29, 2024 with respect to the consolidated financial statements of Ceapro Inc. included in the Form 6-K of Aeterna Zentaris Inc. filed on May 14, 2024. We consent to the incorporation by reference of the said report in the Registration Statements of Aeterna Zentaris Inc. on Form F-3 (File No. 333- 254680) and on Forms S-8 (File No. 333-224737, File No. 333-210561 and File No. 333-200834).

/s/ Raymond Chabot Grant Thornton LLP

Montréal, Canada

May 14, 2024

Member of Grant Thornton International Ltd rcgt.com